Effect of estrogen-progestin hormonal replacement therapy on blood coagulation and fibrinolysis in postmenopausal women

Clinics

Volumn 62, Issue 5, 2007, Pages 553-560

  Bonduki, Claudio E ^a   Lourenço, Dayse M ^a   Da Motta, Eduardo L A ^a   Soares Jr , José Maria ^a   Haidar, Mauro Abi ^a   Baracat, Edmund C ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Antithrombin III; Estrogen; Menopause; Postmenopausal hormonal therapy; Thrombin generation; Thromboembolism

Indexed keywords

ANTITHROMBIN; ANTITHROMBIN III; BIOLOGICAL MARKER; CONJUGATED ESTROGEN; ESTRADIOL; MEDROXYPROGESTERONE ACETATE; THROMBIN;

ADULT; ARTICLE; BLOOD; BLOOD CLOTTING; DRUG EFFECT; ESTROGEN THERAPY; FEMALE; FIBRINOLYSIS; HUMAN; MIDDLE AGED; POSTMENOPAUSE;

ADULT; ANTITHROMBIN III; ANTITHROMBINS; BIOLOGICAL MARKERS; BLOOD COAGULATION; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; FIBRINOLYSIS; HUMANS; MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGED; POSTMENOPAUSE; THROMBIN;

EID: 36448944332     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1807-59322007000500004     Document Type: Article

References (55)

1. Th ed. Philadelphia: Saunders, 2005, p. 42-51.
2. Kaizu K, Abe M. Euglobulin lysis time (ELT).Nippon Rinsho. 2004;62(Suppl 12):584-5.
3. van de Weijer PH, Mattsson LA, Ylikorkala O. Benefits and risks of long-term low-dose oral continuous combined hormone therapy. Maturitas. 2007;56:231-48.
4. Canonico M, Oger E, Plu-Bureau G, Conard J, Meyer G, Levesque H, Trillot N, Barrellier MT, Wahl D, Emmerich J, Scarabin PY; Estrogen and Thromboembolism Risk (ESTHER) Study Group. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation. 2007;115:840-5.
5. Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996;348:977-80.
6. Cushman M, Kuller LH, Prentice R, Rodabough RJ, Psaty BM, Stafford RS, Sidney S, Rosendaal FR; Women's Health Initiative Investigators. Estrogen plus progestin and risk of venous thrombosis.JAMA. 2004;292:1573-80.
7. Hemelaar M, Rosing J, Kenemans P, Thomassen MC, Braat DD, van der Mooren MJ. Less effect of intranasal than oral hormone therapy on factors associated with venous thrombosis risk in healthy postmenopausal women.Arterioscler Thromb Vasc Biol. 2006;26:1660-6.
8. Whitehead M, Godfree V. Venous thrombo-embolism and hormone replacement therapy. Baillieres Clin Obstet Gynaecol 1997;11:587-99.
9. Meade TW. Hormone replacement therapy and haemostatic function. Thromb Haem 1997;78:765-9.
10. Greer IA. Practical strategies for hormone replacement therapy and risk of venous thromboembolism. Br J Obstet Gynaecol 1998;105:376-9.
11. Hulley S, Grady D, Bush T, Fulberg C, Herrington D, Riggs B, et al. For the heart and estrogen/ progestin replacement study (HERS) research group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280:605-13.
12. Writing Group for the Women's Health Initiative Investigators; Risks and benefits of estrogen plus progestina in healthy postmenopausal women. JAMA 2002;288:321-33.
13. The women's health initiative steering committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA 2004;291:1701-1712.
14. Grady D, Herrington D, Brittner V, Blumenthal R, Davidson M, Hlatky M, et al. For the HERS Research Group. Cardiovascular disease outcomes during 6.8 years of hormone theraphy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA. 2002;288:49-57.
15. Herrington DM, Resboussin DM, Brosnihan KB, Sharp PC, Shumaker SA, Snyder TE, et al. Effects of estrogen replacement on the progression of coronary artery atherosclerosis. N Engl J Med 2000;343:522-529.
16. Rosano GM, Vitale C, Silvestri A, Fini M. Hormone replacement therapy and cardioprotection: the end of the tale? Ann N Y Acad Sci. 2003;997:351-7.
17. Teede HJ, McGrath B P, Smolich JJ, Malan E, Kotsopoulou M, Liang YL, et al. Postmenopausal Hormone replacement teraphy increases coagulation activity and fibrinolysis. Arterioscler Thromb Vasc Biol 2000;20:1404-16.
18. Brown NJ, Abbas A, Byrne D, Schoenhard JA, Vaughan DE. Comparative Effects of Estrogen and Angiotensin-Converting Enzyme Inhibition on Plasminogen Activator Inhibitor-1 in Healthy Postmenopausal Women. Circulation. 2002;105:304-9.
19. Gottsater A, Rendell M, Hulthen UL. Hormone replacement theraphy in healthy postmenopausal women: a randomized, placebo-controlled study of effects on coagulation and fibrinolitic factors. J Intern Med. 2001;249:237-46.
20. Perera M, Sattar N, Petrie JR, Hillier C, Small M, Connell JM, et al. The effects of transdermal estradiol in combination with oral norethisterone on lipoproteins, coagulation, and endothelial markers in postmenopausal women with type 2 diabetes: a randomized, placebo-controlled study. J Clin Endocrinol Metab. 2001;86:1140-3
21. Rabbani LE, Seminário NA, Sciacca RR. Oral conjugated equine estrogen increases plasma von Willebrand factor in postmenopausal women. JACC. 2002;40(11):1991-11.
22. Scarabin PY, Oger E, Plu-Bureau G. Differential association of oral and transdermal oestrogenreplacementtherapy with venous thromboembolism risk. Lancet 2003:428-32.
23. Wender MCO, Vitola D, Spritzer PM. Percutaneous 17beta estradiol replacement therapy in hypertensive post-menopausal women. Brazilian Journal of Medical and Biological Research. 1997;30:1047-53.
24. Akhtar N, Deleu D, Kamran S. Haematologic disorders and cerebral venous thrombosis. J Pak Med Assoc. 2006;56:498-501.
25. Petitou M, van Boeckel CA. A synthetic antithrombin III binding pentasaccharide is now a drug! What comes next? Angew Chem Int Ed Engl. 2004;43:3118-33.
26. Bonduki CE, Lourenço DM, Baracat EC, Haidar MA, Noguti MAE, Mota ELA, Lima GR. Effect of estrogen-progestin hormonal replacement therapy on plasma antithrombin III of postmenopausal women. Acta Obstet Gynecol Scand 1998; 77;330-3.
27. Kroon UB, Silfverstolpe G, Tengborn L. The effects of transdermal estradiol and oral conjugated estrogens on haemostasis variables. Thromb Haemost 1994;71:420-3.
28. Dias AR Jr, Melo RN, Gebara OC, D'Amico EA, Nussbacher A, Halbe HW, Pinotti JA. Effects of conjugated equine estrogens or raloxifene on lipid profile, coagulation and fibrinolysis factors in postmenopausal women. Climacteric. 2005;8:63-70
29. Caine YG, Bauer KA, Barzegar S, ten Cate H, Sacks FM, Walsh BW, Schiff I, Rosenberg RD. Coagulation activation following estrogen administration to postmenopausal women. Thromb Haemost 1992;68:392-5.
30. Kessler CM, Szymanski LM, Shamsipour Z, Muesing RA, Miller VT, LaRosa JC. Estrogen replacement therapy and coagulation: relationship to lipid and lipoprotein changes. Obstet Gynecol. 1997;89:326-31.
31. Aldrighi JM, De Campos LS, Eluf Gebara OC, Petta CA, Bahamondes L. Effect of a combined oral contraceptive containing 20 microg ethinyl estradiol and 75 microg gestodene on hemostatic parameters. Gynecol Endocrinol. 2006;22:1-4.
32. Gordon EM, Williams SR, Frenchek B, Mazur CA, Speroff L. Dose-dependent effects of postmenopausal estrogen and progestin on antithrombin III and factor XII. J Lab Clin Med 1988;111:52-6.
33. Lindberg UB, Crona N, Stigendal L, Teger-Nilsson AC, Silfverstolpe G. A comparison between effects of estradiol valerate and low dose ethinyl estradiol on haemostasis parameters. Thromb Haemost 1989;61:65-9.
34. Gilabert J, Estelles A, Cano A, Espana F, Barrachin AR, Grancha S, Aznar J, Tortajada M. The effect of estrogen replacement therapy with or without progestogen on the fibrinolytic system and coagulation inhibitors in postmenopausal status. Am J Obstet Gynecol 1995;173:1849-54.
35. Enzelsberger H, Heytmanek G, Kurz C, Metka M. Hormone replacement therapy and its influence on AT-III activity in climacteric women. Klin Wochenschr 1991;69:232.
36. Sporrong T, Mattsson LA, Samsioe G, Stigendal L, Hellgren M. Haemostatic changes during continuous oestradiol-progestogen treatment of postmenopausal women. Br J Obstet Gynaecol 1990;97:939-44.
37. Mannucci PM, Tripodi A. Mechanisms, markers and management of hypercoagulable states. Haemostasis 1996;26(suppl 4):1-8.
38. Stegnar M, Cuderman TV, Bozic M. Evaluation of pre-analytical, demographic, behavioural and metabolic variables on fibrinolysis and haemostasis activation markers utilised to assess hypercoagulability. Clin Chem Lab Med. 2007;45:40-6.
39. Nekludov M, Antovic J, Bredbacka S, Blomback M. Coagulation abnormalities associated with severe isolated traumatic brain injury: cerebral arterio-venous differences in coagulation and inflammatory markers. J Neurotrauma. 2007;24:174-80.
40. Saleh AA, Dorey LG, Dombrowski MP. Thrombosis and hormone replacement therapy in postmenopausal women. Am J Obstet Gynecol 1993;169:1554-1557.
41. Brosnan JF, Sheppard BL, Norris LA. Haemostatic activation in postmenopausal women taking low-dose hormone therapy: Less effect with transdermal administration? Thromb Haemost. 2007;97:558-565
42. Meade TW, Berra A. Hormone replacement therapy and cardiovascular disease. Br Med Bull 1992; 48:276-308.
43. Meilahn EN, Cauley JA, Tracy RP, Macy EO, Gutai JP, Kuller LH. Association of sex hormones and adiposity with plasma levels of fibrinogen and PAI-1 in postmenopausal women. Am J Epidemiol 1996; 143:159-66.
44. Nabulsi AA, Folsom AR, White A, Patsch W, Heiss G, Wu KK, Szklo M. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. The Atherosclerosis Risk in Communities Study Investigators. N Engl J Med 1993;328:1069-75.
45. Fait T, Vrablik M, Cibula D, Masata J, Hill M, Trnkova B. Oral but not transdermal estrogen replacement therapy reduced level of tissue factor pathway inhibitor: cross-over designed study. Neuro Endocrinol Lett. 2006;27:665-8.
46. van Wersch JW, Ubachs JM, van den Ende A, van Enk A. The effect of two regimens of hormone replacement therapy on the haemostatic profile in postmenopausal women. Eur J Clin Chem Clin Biochem 1994;32:449-53.
47. Gebara OC, Mittleman MA, Sutherland P, Lipinska I, Matheney T, Xu P, Welty PW, Levy D, Muller JE. Association between increased estrogen status and increased fibrinolytic potencial in the Framingham Offspring Study. Circulation 1995;9:1952-1958.
48. Shahar E, Folsom AR, Saloma W, Stinson VL, Mcgovern PG, Shimakawa T, Chambless LE, Wu KK. Relation of hormone replacement therapy to measures of plasma fibrinolytic activity. Atherosclerosis Risk in Communities (ARIC) Study Investigators. Circulation 1996;93:1970-5.
49. Koh KK, Jin DK, Yang SH, Lee SK, Hwang HY, Kang MH, Kim W, Kim DS, Choi IS, Shin EK. Vascular effects of synthetic or natural progestagen combined with conjugated equine estrogen in healthy postmenopausal women. Circulation. 2001;103:1961-6.
50. Hu P, Greendale GA, Palla SC, Reboussin BA, Henrrington DM, Barret-Connor E, et al. The effects of hormone therapy on the markers of inflammation and endothelial function and plasma matrix metalloproteinase-9 level in postmenopausal women: The postmenopausal estrogen progestin intervention (PEPI) trial. Atherosclerosis. 2006;185:347-52.
51. Sumino H, Ichikava S, Kasama S, Takahashi T, Kumakura H, Takayama Y, et al. Different effects of oral conjugated estrogen and transdermal estradiol on arterial stiffness and vascular inflammatory markers in postmenopausal women. Atherosclerosis 2006; In Press.
52. Wakatsuki A, Ikenoue N, Shinohara K. Effect of Lower Dosage of Oral Conjugated Equine Estrogen on Inflammatory Markers and Endothelial Function in Healthy Postmenopausal Women. Arterioscler Thromb Vasc Biol, 2004;24:571-576.
53. Wakatsuki A, Okatani Y, Ikenove N, Fukaya T. Effect of Medroxyprogesterone Acetate on Vascular Inflammatory Markers in Postmenopausal Women Receiving Estrogen. Circulation 2002;105:1436.
54. Duschek Ejj, Stehouwer CDA, Valk-DE Roo, GW. Raloxifene, conjugated oestrogen and endothelial function in postmenopausal women. J Intern Med. 2003;254:85-94
55. Lima SMR, Aldrighi JM, Consolin-Colombo FM, Mansur A, Rubira MC, Krieger EM, et al. Acute administration of 17b-estradiol improves endothelium-dependent vasodilation in postmenopausal women. Maturitas. 2005;50:266-74.